Table 1 Data items and characterization
From: Identification of asymptomatic Leishmania infections: a scoping review
Data item | Characterization |
|---|---|
Author | Last name of first author |
Year | Year of publication |
WHO region | WHO region where study was conducted: European Region, Americas, Eastern Mediterranean Region, South-East Asia, African Region |
Country | The country or countries where the study was conducted |
Objective of study | As outlined by the authors. This was extracted verbatim and subsequently thematically characterized into analyzable data items, e.g., prevalence survey, test validation, etc. |
Population description | Description of the study population, including the methods of selection, e.g., household contacts, blood donors and volunteers |
Population size | The size of the sampled population |
Leishmania manifestation | The clinical manifestation of Leishmania applied to determine symptomatology, including visceral (VL), cutaneous (CL), and post-kala-azar dermal leishmaniasis (PKDL) |
Clinical status | The overall clinical status of the study population, including: immunocompetent (IC), immunosuppressed (IS), HIV-infected (HIV), and solid organ transplant (SOT) |
History of clinical Leishmania disease | Whether a history of previous leishmaniasis was confirmed in the study population |
Leishmania species | The species of Leishmania under investigation. These include L. donovani, L. infantum, L. major, L. chagasi, L. braziliensis, L. amazonensis, L. mexicana, L. guyanensis, L. panamensis |
Diagnostic test used | The diagnostic test used by the investigators, as reported in the manuscript |
Definition of asymptomatic disease | As reported directly by the authors where available; alternatively, an implicit definition was inferred from information available in the manuscript |